Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AN2718 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | AN2718 Cream SF Vehicle |
| B | EXPERIMENTAL | AN2718 Cream SF, 0.3% |
| C | EXPERIMENTAL | AN2718 Cream SF, 1% |
| D | EXPERIMENTAL | AN2718 Gel Vehicle |
| E | EXPERIMENTAL | AN2718 Gel, 1.5% |
| F | EXPERIMENTAL | AN2718 Gel, 2.5% |
| G | EXPERIMENTAL | AN2718 Gel, 5% |
| H | EXPERIMENTAL | AN2718 Gel, 7.5% |
| I | ACTIVE_COMPARATOR | Sodium Lauryl Sulfate, 0.5% |
| Name | Type | Description |
|---|---|---|
| AN2718 | OTHER | AN2718 Cream SF Vehicle, Daily for up to 21 days |
| Sodium Lauryl Sulfate | OTHER | Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days |
Inclusion Criteria: Subjects must meet all of the following criteria for inclusion in the study. 1. Healthy volunteers of either sex, at least 18 years of age or older. 2. Females must be of non-childbearing potential (i.e., post-menopausal or surgically sterile \[bilateral oophorectomy and/or tot...
AN2718 is an investigational small molecule being developed for the treatment of tinea pedis, commonly known as athlete's foot. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
AN2718 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
AN2718 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been completed.
AN2718 has one completed Phase 1 clinical trial, identified as NCT00781664, titled "Cumulative Irritation Test." The trial enrolled 44 participants in the United States, including healthy volunteers aged 18 years and older.
No alternative names for AN2718 have been reported. The drug is identified solely by its code name AN2718 and is being developed by Pfizer, Inc. for the treatment of tinea pedis.